« Return to News | Drug Sponsors | Study Conduct

Yale and Gilead Sciences announce cancer research collaboration

Wednesday, March 30, 2011 01:40 PM

California-based Gilead Sciences and Yale School of Medicine have announced a research collaboration focused on the discovery of new cancer therapies, according to FierceBiotech.

"The collaboration brings together one of the world's top research universities and a biopharmaceutical company dedicated to addressing unmet medical needs with the goal of finding new treatments for cancer," president of Yale Richard C. Levin said.

Initially, the partnership will span four years and includes an option to renew for up to ten years. Gilead will support the endeavor with $40 million in research support and basic science infrastructure development for the first four years; it may provide up to $100 million over ten years if the pact continues. Gilead has the first option to license resulting inventions from the collaboration.

"Following Gilead's recent acquisitions of cancer development programs, this partnership serves to strengthen our discovery capabilities in the area of oncology," said Norbert W. Bischofberger, Ph.D., Gilead's executive vice president, research and development and chief scientific officer. "Based on the strong track-record of the Yale cancer research team, I am confident this collaboration will lead to important advances in the understanding of the genetic basis of cancer as we collectively seek to develop novel targeted therapies for patients in areas of unmet medical need."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.